Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice

Henry T. Lau, Ming Yu, Adriano Fontana, Christian J. Stoeckert

Research output: Contribution to journalArticle

Abstract

Allogeneic transplantation of islets of Langerhans was facilitated by the cotransplantation of syngeneic myoblasts genetically engineered to express the Fas ligand (FasL). Composite grafting of allogeneic islets with syngeneic myoblasts expressing FasL protected the islet graft from immune rejection and maintained normoglycemia for more than 80 days in mice with streptozotocin-induced diabetes. Graft survival was not prolonged with composite grafts of unmodified myoblasts or Fas-expressing myoblasts. Islet allografts transplanted separately from FasL-expressing myoblasts into the contralateral kidney were rejected, as were similarly transplanted third- party thyroid allografts. Thus, the FasL signal provided site- and immune- specific protection of islet allografts.

Original languageEnglish (US)
Pages (from-to)109-112
Number of pages4
JournalScience
Volume273
Issue number5271
StatePublished - Jul 5 1996

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice'. Together they form a unique fingerprint.

  • Cite this

    Lau, H. T., Yu, M., Fontana, A., & Stoeckert, C. J. (1996). Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science, 273(5271), 109-112.